# Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

> **NCT02608528** · — · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 10 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **RADIATION:** [18F]fluoroglucose(FDG)

## Key facts

- **NCT ID:** NCT02608528
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-22
- **Primary completion:** 2019-07-18
- **Final completion:** 2019-07-18
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Poor Accrual
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608528, "Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02608528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*